---
title: Exposure Therapy Consortium (ETC) for Anxiety Sensitivity
nct_id: NCT05225740
overall_status: COMPLETED
phase: NA
sponsor: University of Texas at Austin
study_type: INTERVENTIONAL
primary_condition: Elevated Anxiety Sensitivity
countries: United States, Australia, Germany, Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05225740.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05225740"
ct_last_update_post_date: 2025-04-29
last_seen_at: "2026-05-12T06:02:49.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Exposure Therapy Consortium (ETC) for Anxiety Sensitivity

**Official Title:** Large-group One-session Exposure Therapy Protocol for Targeting Anxiety Sensitivity

**NCT ID:** [NCT05225740](https://clinicaltrials.gov/study/NCT05225740)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 399
- **Lead Sponsor:** University of Texas at Austin
- **Collaborators:** University of North Carolina, Chapel Hill, University of Colorado, Boulder, University of Miami, University of Mississippi, Oxford, Ruhr University of Bochum, Boston University, Fordham University, The University of New South Wales, Southern Methodist University, Institute of Behavioral-Therapy and -Medicine at the Philipps University Marburg, Technische Universität Dresden, Curtin University, Hebrew University of Jerusalem, University of Göttingen
- **Conditions:** Elevated Anxiety Sensitivity
- **Start Date:** 2022-10-01
- **Completion Date:** 2024-07-01
- **CT.gov Last Update:** 2025-04-29

## Brief Summary

The current study seeks to test differences between a single-session large-group format of standard exposure, enhanced exposure, and a control condition in treating anxiety sensitivity. It is hypothesized that 1) participants assigned to either exposure condition will evidence greater reductions in anxiety sensitivity from pre-treatment to posttreatment relative to those in the control condition; 2) participants assigned to the enhanced exposure condition will evidence greater reductions in anxiety sensitivity from pre-treatment to posttreatment relative to those in the standard exposure condition. The investigators will test putative moderators and mechanisms of action. Prior to initiating the study for purposes of data analyses, the investigators will pilot study procedures during Spring 2020.

## Detailed Description

Anxiety sensitivity (AS), or the fear of anxiety and related sensations, represents an individual difference variable implicated in the risk and maintenance of anxiety and related disorders. Best conceptualized as an amplification factor, AS, when elevated, interacts with changes in bodily sensations (e.g., racing heart, sweating, dizziness) to produce fear. Exposure therapy involves repeated confrontation to feared cues to help individuals reestablish a sense of safety around these cues. Exposure therapy is a transdiagnostic treatment strategy that has shown to be efficacious across anxiety and related disorders. Symptom induction exercises (e.g., spinning, voluntary hyperventilation, straw breathing, using a tongue depressor) are useful for providing exposure to benign bodily sensations (e.g., dizziness, racing heart, breathlessness, choking), allowing individuals with elevated AS to learn that, while perhaps uncomfortable, these sensations are not harmful, but safe.

In an effort to increase the access to exposure therapy, Margraf and colleagues developed a large-group one-session exposure therapy protocols involving brief psychoeducation followed by either observation or participation in exposure practice for fears of various cues, including spiders, dental procedures, and blood, injuries and injections. Initial testing indicates feasibility and shows that individuals participating in these protocols evidence significant improvement in anxiety symptoms.

The current study involves the development and testing of a large-group one-session exposure therapy protocol designed to target AS. The investigators will compare two variants of the protocol and include a general stress reduction protocol as a control condition (CONTROL). The first variant (STANDARD) is a standard protocol, modeled after those developed by Margraf and colleagues, that includes a combination of psychoeducation (about the nature and \[exposure\] therapy of anxiety sensitivity) and interoceptive exposure therapy modeling and practice. The second variant (ENHANCED) is identical to the first but also includes post-exposure practice processing aimed at facilitating threat reappraisal (i.e., safety learning). All interventions will be delivered in large-group format (N ≥ 25 participants) by a team of clinicians (N = 3) trained in the delivery of exposure therapy. In an effort to improve the quality of research on exposure therapy, another central aim of this study is to examine the feasibility of an exposure therapy consortium. The investigators have established a network of research sites (N=11) with expertise in exposure therapy. With UT as the coordinating site, the investigators propose to implement the study protocol at each of these sites, allowing us to obtain the data needed to examine replication and the identification of predictors, moderators and mediators of treatment effects.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Ages 18-70
* Students currently enrolled in enrolled in an introductory psychology course a psychology course
* Elevated anxiety sensitivity (total ASI-3 score ≥ 23)

Exclusion Criteria:

\- History of respiratory or cardiovascular conditions (e.g., asthma, high blood pressure), neurological disorders (e.g., epilepsy), current pregnancy, or medical problems (e.g., inner ear problems, back or joint problems) that may interfere with an ability complete interoceptive exposure procedures
```

## Arms

- **Control** (ACTIVE_COMPARATOR) — General stress reduction based on stress management training to help people cope with feelings of anxiety, used as an active control condition
- **Standard Exposure** (ACTIVE_COMPARATOR) — Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and completion of questions about the exercises and the large-group aspect
- **Enhanced Exposure** (EXPERIMENTAL) — Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and post-exposure processing aimed at emphasizing harm expectancy violation

## Interventions

- **Standard Exposure** (BEHAVIORAL) — The standard intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a post-exposure exercise. The post-exposure exercise will involve completing a set of questions regarding the exercises and the group experience.
- **Stress Management Training** (BEHAVIORAL) — Stress management training (SMT) is designed to help people better cope with feelings of anxiety that accompany high levels of anxiety sensitivity. SMT will involve group instruction in healthy ways to experience and cope with stress whenever difficult situations arise. Participants will teach participants ways to maintain a healthy lifestyle, targeting things like nutrition, exercise, and sleep hygiene. This intervention will also involve progressive muscle relaxation training.
- **Enhanced Exposure** (BEHAVIORAL) — The enhanced intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a processing exercise. The post-processing exercise will involve completing a set of questions that will highlight harm expectancy violations.

## Primary Outcomes

- **Anxiety Sensitivity** _(time frame: 1 day)_ — The primary outcome is Anxiety Sensitivity at the posttreatment endpoint. Anxiety Sensitivity will be measured with the Anxiety Sensitivity Index-3 scale (ASI-3; 0-72, lower scores mean better outcome).

## Secondary Outcomes

- **Change in Anxiety Sensitivity** _(time frame: 1 month)_
- **Depression** _(time frame: 1 month)_
- **Anxiety** _(time frame: 1 month)_

## Locations (12)

- The University of Colorado at Boulder, Boulder, Colorado, United States
- The University of Miami, Miami, Florida, United States
- Boston University, Boston, Massachusetts, United States
- The University of Mississippi, Oxford, Mississippi, United States
- The University of Texas at Austin, Austin, Texas, United States
- University of New South Wales, Kensington, Australia
- Curtin University, Perth, Australia
- Philipps-Universität Marburg, Marburg, Hesse, Germany
- Ruhr-Universität Bochum, Bochum, Ruhr Region, Germany
- Technische Universität Dresden, Dresden, Saxony, Germany
- University of Göttingen, Göttingen, Germany
- The Hebrew University of Jerusalem, Jerusalem, Israel

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the university of colorado at boulder|boulder|colorado|united states` — added _(2026-05-12)_
- `locations.the university of miami|miami|florida|united states` — added _(2026-05-12)_
- `locations.boston university|boston|massachusetts|united states` — added _(2026-05-12)_
- `locations.the university of mississippi|oxford|mississippi|united states` — added _(2026-05-12)_
- `locations.the university of texas at austin|austin|texas|united states` — added _(2026-05-12)_
- `locations.university of new south wales|kensington||australia` — added _(2026-05-12)_
- `locations.curtin university|perth||australia` — added _(2026-05-12)_
- `locations.philipps-universität marburg|marburg|hesse|germany` — added _(2026-05-12)_
- `locations.ruhr-universität bochum|bochum|ruhr region|germany` — added _(2026-05-12)_
- `locations.technische universität dresden|dresden|saxony|germany` — added _(2026-05-12)_
- `locations.university of göttingen|göttingen||germany` — added _(2026-05-12)_
- `locations.the hebrew university of jerusalem|jerusalem||israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05225740.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05225740*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*